Navigation Links
INVO Bioscience Completes Reverse Merger
Date:2/25/2009

Shares trading under IVOB symbol on OTCBB

BEVERLY, Mass., Feb. 25 /PRNewswire-FirstCall/ -- INVO Bioscience, Inc. ("INVO Bioscience" or "the company"), focused on creating simplified, lower cost treatment option for patients diagnosed with infertility, announced the closing of its reverse merger with Emy's Salsa Aji Distribution Company, Inc. (OTC Bulletin Board: EMYS.OB). Through this transaction, INVO Bioscience, formerly BioXcell becomes a public reporting company and its common stock is listed on the OTCBB under the newly-assigned symbol (OTC Bulletin Board: IVOB). The INVO Bioscience executive team will operate the new company focusing on INVOcell sales globally.

"This is a significant step in the growth of our company," said Kathleen Karloff, Chief Executive Officer of INVO Bioscience. "We are now positioned to execute our vision of providing an innovative, more affordable infertility treatment option to the millions of infertile men and women around the world".

"The INVOcell is a novel medical device that enables egg fertilization and early embryo development in the woman's vaginal cavity. The INVO Procedure will be an important option for patients who cannot afford conventional infertility treatments, enabling more patients to seek treatment and build families," added Claude Ranoux, MD, MS, Founder, President and Chief Scientist, INVO Bioscience.

For additional information about this transaction, see the company's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on February 17, 2009 at www.sec.gov.

About the INVOcell Procedure

The INVOcell and INVO Procedure combine a natural or mild stimulation infertility treatment cycle, using lower amounts of injectable fertility hormones than used in traditional IVF(in vitro fertilization), with intra-vaginal incubation (IVC) of sperm and eggs. Following standard egg retrieval, the woman's eggs (oocytes) are combined with sperm in the INVOcell, a small biological capsule, which is then sealed and placed in the woman's vaginal cavity to incubate for three days. When the INVOcell is removed, any developing embryos are transferred directly into the woman's uterine cavity, where implantation and continued pregnancy can take place.

The company has received European CE Mark approval for the INVOcell and, in 2008, launched the product in select countries outside the U.S. The company is also pursuing U.S. Food and Drug Administration approval for the INVOcell.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE INVO Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... ... 18, 2016 , ... Tech Coast Angels (TCA) today announced that ... at the annual ACA Summit last week in Philadelphia. , The award ... member angel groups. It is the highest honor available for an early-stage company to ...
(Date:5/18/2016)... NEW YORK , May 18, 2016 ... challenges, but it does not mean that there are no ... equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD ), Seattle ... CHMA ), and Ophthotech Corp. (NASDAQ: ... and trading alerts at: http://www.activewallst.com/ ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, more than 5,400 ... complications.* Costing more than $56 billion in direct costs annually, asthma remains a ... many, the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and better ...
(Date:5/18/2016)... ... May 18, 2016 , ... Ryan Benton was diagnosed with Duchenne Muscular ... late teens to early twenties. DMD is a relatively common progressive genetic disorder, which ... 22, Benton’s condition was critical. He met with the founder of the Stem ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/15/2016)... -- --> --> According ... "Digital Door Lock Systems Market - Global Industry Analysis, Size, ... digital door lock systems market in terms of revenue was ... to grow at a CAGR of 31.8% during the period ... (MSMEs) across the world and high industrial activity driving inclusive ...
Breaking Biology News(10 mins):